161262-45-9

Usage

Uses

Used in Pharmaceutical Industry:
3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one hydrochloride (1:1) is used as a potential pharmacological agent for its possible biological activities. Due to its complex structure and the presence of a furochromenone core, it may exhibit properties that could be beneficial in the development of new drugs or therapeutic agents.
Used in Research and Development:
3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one hydrochloride (1:1) is used as a research compound for studying its chemical properties and potential interactions with biological systems. Its unique structure may provide insights into the development of new chemical entities with therapeutic potential.

Synthetic route

trioxsalen (3902-71-4) → 4'-(4-amino-2-oxa)butyl-4,5',8-trimethylpsoralen Hydrochloride (161262-45-9)

Upstream product

• 3902-71-4 trioxsalen 

Relevant academic research and scientific papers

Methods and devices for the removal of psoralens from blood products

Methods and devices for the removal of psoralens and psoralen photoproducts from blood products are described. The methods include contacting a psoralen- and irradiation-treated blood product with a resin capable of adsorbing psoralens and psoralen photoproducts. The removal process is particularly suitable for use with platelet concentrates and plasma because the process does not have a significant adverse effect on clotting factor function. The methods and devices can be incorporated with apheresis systems and other devices and procedures currently used to process blood products for transfusion.

Method and devices for the removal of psoralens from blood products

Method for removing a pathogen-inactivating compound such as psoralen from a biological fluid such as blood or a blood product. One such method involves treating a blood product which contains a nucleic acid-containing pathogen to be inactivated. This method includes adding a pathogen-inactivating compound such as psoralen to the blood product; irradiating the psoralen and the blood product to form a mixture comprising the blood product, free psoralen, and low molecular weight psoralen photoproducts; and contacting the mixture with a hypercrosslinked resin to remove at least substantially all of the free psoralen and the low molecular weight psoralen photoproducts. A hypercrosslinked resin in this method preferably eliminates a wetting step that a number of other types of resins require before being used to adsorb the pathogen inactivating compound.

Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.

Compounds for the photodecontamination of pathogens in blood

Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.